{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:31:58Z","timestamp":1793331118227,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41401-026-01964-w","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:24:56Z","timestamp":1792733096000},"page":"3099-3101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anticancer drug discovery: Embracing the next wave of innovation"],"prefix":"10.1038","volume":"47","author":[{"given":"Min","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-yu","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"1964_CR1","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41573-023-00723-4","volume":"22","author":"EC Scott","year":"2023","unstructured":"Scott EC, Baines AC, Gong Y, Moore R Jr, Pamuk GE, Saber H, et al. Trends in the approval of cancer therapies by the FDA in the twenty-first century. Nat Rev Drug Discov. 2023;22:625\u201340.","journal-title":"Nat Rev Drug Discov"},{"key":"1964_CR2","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41392-025-02267-y","volume":"10","author":"R Tan","year":"2025","unstructured":"Tan R, Hua H, Zhou S, Yang Z, Yang C, et al. Current landscape of innovative drug development and regulatory support in China. Signal Transd Target Ther. 2025;10:220.","journal-title":"Signal Transd Target Ther"},{"key":"1964_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-026-01868-9","author":"R Wang","year":"2026","unstructured":"Wang R, Chen Y, Fang YF. Dendritic cell diversity and dysfunction in cancer: implications for immunotherapy and therapeutic targeting. Acta Pharmacol Sin. 2026.\u00a0https:\/\/doi.org\/10.1038\/s41401-026-01868-9.","journal-title":"Acta Pharmacol Sin"},{"key":"1964_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-026-01820-x","author":"Q Miao","year":"2026","unstructured":"Miao Q, Chen R, Zhang DM, Zhang JQ, Chen MF. The vascular niche: an orchestrator of the spatiotemporal dynamics of distant metastasis. Acta Pharmacol Sin. 2026. https:\/\/doi.org\/10.1038\/s41401-026-01820-x.","journal-title":"Acta Pharmacol Sin"},{"key":"1964_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-026-01815-8","author":"ZH Zhang","year":"2026","unstructured":"Zhang ZH, Ding ZY, Chen LY, Fu YX, Huang M. Solute carrier transporters as metabolic gatekeepers in tumor-microenvironment crosstalk. Acta Pharmacol Sin. 2026. https:\/\/doi.org\/10.1038\/s41401-026-01815-8.","journal-title":"Acta Pharmacol Sin"},{"key":"1964_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-026-01882-x","author":"XY Li","year":"2026","unstructured":"Li XY, Xie ZQ, Geng MY. Gut microbiota modulation of gastrointestinal cancers: from dysbiosis signatures to therapeutic interventions. Acta Pharmacol Sin. 2026. https:\/\/doi.org\/10.1038\/s41401-026-01882-x.","journal-title":"Acta Pharmacol Sin"},{"key":"1964_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-026-01855-0","author":"Y Chen","year":"2026","unstructured":"Chen Y, Liu QP, Yang SJ, Ding J, Lu XY, Xie H. Opportunities and challenges in the development of evolving EGFR inhibitors to overcome EGFR TKIs resistance. Acta Pharmacol Sin. 2026. https:\/\/doi.org\/10.1038\/s41401-026-01855-0.","journal-title":"Acta Pharmacol Sin"},{"key":"1964_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-026-01835-4","author":"W Zhao","year":"2026","unstructured":"Zhao W, Pan JX. Epigenetic plasticity in cancer drug resistance: mechanistic insights and strategies for therapeutic intervention. Acta Pharmacol Sin. 2026. https:\/\/doi.org\/10.1038\/s41401-026-01835-4.","journal-title":"Acta Pharmacol Sin"},{"key":"1964_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-026-01803-y","author":"B Zhan","year":"2026","unstructured":"Zhan B, Zhang HL, Xiao Y, Zhong WQ, Guo YQ, Shan JL, et al. Cell death pathways and targeting therapeutics in cancer therapy. Acta Pharmacol Sin. 2026. https:\/\/doi.org\/10.1038\/s41401-026-01803-y.","journal-title":"Acta Pharmacol Sin"},{"key":"1964_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-026-01757-1","author":"QK Zhang","year":"2026","unstructured":"Zhang QK, Cao JZ, Zhao W. Pharmacological targeting of oncogenic condensates in cancer: mechanistic insights and therapeutic opportunities. Acta Pharmacol Sin. 2026. https:\/\/doi.org\/10.1038\/s41401-026-01757-1.","journal-title":"Acta Pharmacol Sin"},{"key":"1964_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-026-01860-3","author":"CX Zhao","year":"2026","unstructured":"Zhao CX, Wang SY, Li K. Molecular mechanisms for sustaining cancer stem cells characteristics and targeted therapeutic strategies. Acta Pharmacol Sin. 2026. https:\/\/doi.org\/10.1038\/s41401-026-01860-3.","journal-title":"Acta Pharmacol Sin"},{"key":"1964_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-026-01861-2","author":"YB Zhang","year":"2026","unstructured":"Zhang YB, Fu JW, Liu Y, Wu RL, Liang YT, Zhang WH, et al. Targeted protein degradation: bridging chemical biology and clinical translation. Acta Pharmacol Sin. 2026. https:\/\/doi.org\/10.1038\/s41401-026-01861-2.","journal-title":"Acta Pharmacol Sin"},{"key":"1964_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-026-01866-x","author":"XZ Xiao","year":"2026","unstructured":"Xiao XZ, Wang YJ, Pang XF, Zhang A. Evolution of KRAS molecular glues: from allele-selective to Pan-RAS and protein-protein interaction modulators. Acta Pharmacol Sin. 2026. https:\/\/doi.org\/10.1038\/s41401-026-01866-x.","journal-title":"Acta Pharmacol Sin"},{"key":"1964_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-026-01877-8","author":"H Chen","year":"2026","unstructured":"Chen H, Fu R, Wu ZQ. Transcription factor targeting strategies in cancer: mechanisms, challenges and cutting-edge progress. Acta Pharmacol Sin. 2026. https:\/\/doi.org\/10.1038\/s41401-026-01877-8.","journal-title":"Acta Pharmacol Sin"},{"key":"1964_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-026-01867-w","author":"XT Liu","year":"2026","unstructured":"Liu XT, Tang F, Huang W. Recent advances in function-enhanced antibody-drug conjugates: Antibody optimization and payload combination. Acta Pharmacol Sin. 2026. https:\/\/doi.org\/10.1038\/s41401-026-01867-w.","journal-title":"Acta Pharmacol Sin"},{"key":"1964_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-026-01928-0","author":"D Di","year":"2026","unstructured":"Di D, Li LF, He TY, Cui HX, Nian Y, Jiao X, et al. Therapeutic cancer vaccines: development, challenges, and future perspectives. Acta Pharmacol Sin. 2026. https:\/\/doi.org\/10.1038\/s41401-026-01928-0.","journal-title":"Acta Pharmacol Sin"},{"key":"1964_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-026-01805-w","author":"JY Liu","year":"2026","unstructured":"Liu JY, Yang DL, Liu HY, Xiang SF, Cao J, Yang B, et al. Advances in targeted therapies for pediatric tumors. Acta Pharmacol Sin. 2026. https:\/\/doi.org\/10.1038\/s41401-026-01805-w.","journal-title":"Acta Pharmacol Sin"},{"key":"1964_CR18","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1056\/NEJMoa2505783","volume":"394","author":"BM Wolpin","year":"2026","unstructured":"Wolpin BM, Park W, Garrido-Laguna I, Spira A, Starodub A, Sommerhalder D, et al. Daraxonrasib in previously treated advanced RAS-mutated pancreatic cancer. N Engl J Med. 2026;394:1790\u2013802.","journal-title":"N Engl J Med"},{"key":"1964_CR19","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","volume":"405","author":"C Qi","year":"2025","unstructured":"Qi C, Liu C, Peng Z, Zhang Y, Wei J, Qiu W, et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet. 2025;405:2049\u201360.","journal-title":"Lancet"},{"key":"1964_CR20","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403:632\u201344.","journal-title":"Lancet"},{"key":"1964_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189467","volume":"1880","author":"H Hendriks","year":"2025","unstructured":"Hendriks H. Advancing oncology drug development: Innovative approaches to enhance success rates while reducing animal testing. Biochim Biophys Acta Rev Cancer. 2025;1880:189467.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1964_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-021-00301-6","volume":"21","author":"A Honkala","year":"2022","unstructured":"Honkala A, Malhotra SV, Kummar S, Junttila MR. Harnessing the predictive power of preclinical models for oncology drug development. Nat Rev Drug Discov. 2022;21:99\u2013114.","journal-title":"Nat Rev Drug Discov"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01964-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01964-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01964-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:08:10Z","timestamp":1793329690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01964-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1964"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01964-w","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"29 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jian Ding is the editor-in-chief of the journal and was not involved in the peer review or the decision making of the article. The authors declare no other competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}